Orotracheal treprostinil administration attenuates bleomycin‐induced lung injury, vascular remodeling, and fibrosis in mice
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
Pulmonary fibrosis is a progressive disease characterized by disruption of lung architecture and deregulation of the pulmonary function. Prostacyclin, a metabolite of arachidonic acid, is a potential disease mediator since it exerts anti‐inflammatory and anti‐fibrotic actions. We investigated the effect of treprostinil, a prostacyclin analogue, in bleomycin‐induced experimental pulmonary fibrosis. Bleomycin sulfate or saline was administrated intratracheally to mice ( n = 9–10/group) at day 0. Orotracheal aspiration of treprostinil or vehicle was administered daily and started 24 h prior to bleomycin challenge. Evaluation of lung pathology was performed in tissue samples and bronchoalveolar lavage fluid collected 7, 14 and 21 days after bleomycin exposure. Lung injury was achieved due to bleomycin exposure at all time points as indicated by impaired lung mechanics, pathologic lung architecture (from day 14), and cellular and protein accumulation in the alveolar space accompanied by a minor decrease in lung tissue VE‐cadherin at day 14. Treprostinil preserved lung mechanics, and reduced lung inflammation, fibrosis, and vascular remodeling (day 21); reduced cellularity and protein content of bronchoalveolar lavage fluid were additionally observed with no significant effect on VE‐cadherin expression. Bleomycin‐induced collagen deposition was attenuated by treprostinil from day 14, while treprostinil involvement in regulating inflammatory processes appears mediated by NF‐κB signaling. Overall, prophylactic administration of treprostinil, a stable prostacyclin analogue, maintained lung function, and prevented bleomycin‐induced lung injury, and fibrosis, as well as vascular remodeling, a hallmark of pulmonary hypertension. This suggests potential therapeutic efficacy of treprostinil in pulmonary fibrosis and possibly in pulmonary hypertension related to chronic lung diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A phase 1 trial (ACTRN12619001239156) was completed and demonstrated treatment-related GI adverse events, but no serious adverse events were reported [125].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [125]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654 · cited 1×
“Several multicenter clinical trials have been conducted for IPF, but only two drugs (pirfenidone and nintedanib) were proved to be effective as disease-modifying therapies.(5) However, for a number of patients the only effective treatment will still be lung transplantation.”
BackgroundHaemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
SIMONNEAU, G., BARST, R. J., GALIE, N., NAEIJE, R., RICH, S., BOURGE, R. C., KEOGH, A., OUDIZ, R., FROST, A., BLACKBURN, S. D., et al. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.6.2106079 · Cited by 1,441
Standardized Quantification of Pulmonary Fibrosis in Histological Samples
Hübner, R.-H., Gitter, W., Eddine El Mokhtari, N., Mathiak, M., Both, M., Bolte, H., Freitag-Wolf, S., & Bewig, B. (2008) · BioTechniques · doi:10.2144/000112729 · Cited by 817 · cited 2×
“Aschroft test was used for the quantification of fibrotic injury in the lung according to Hubner et al.(21)”
MethodPulmonary hypertension in chronic lung disease and hypoxia
Nathan, S. D., Barbera, J. A., Gaine, S. P., Harari, S., Martinez, F. J., Olschewski, H., Olsson, K. M., Peacock, A. J., Pepke-Zaba, J., Provencher, S., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01914-2018 · Cited by 757
Up-Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary Fibrosis
Pardo, A., Gibson, K., Cisneros, J., Richards, T. J., Yang, Y., Becerril, C., Yousem, S., Herrera, I., Ruiz, V., Selman, M., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020251 · Cited by 489
Kaminski, N., Allard, J. D., Pittet, J. F., Zuo, F., Griffiths, M. J. D., Morris, D., Huang, X., Sheppard, D., & Heller, R. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1778 · Cited by 417
Fukuhara, S., Sakurai, A., Sano, H., Yamagishi, A., Somekawa, S., Takakura, N., Saito, Y., Kangawa, K., & Mochizuki, N. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.1.136-146.2005 · Cited by 409
Wilborn, J., Crofford, L. J., Burdick, M. D., Kunkel, S. L., Strieter, R. M., & Peters-Golden, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117866 · Cited by 392
Research works printed but not linked: 2
- 10.1002/(sici)1097-4644(19981101)71:2<254::aid-jcb10>3.0.co;2-l · doi:10.1002/(sici)1097-4644(19981101)71:2<254::aid-jcb10>3.0.co;2-l
- Manitsopoulos N, 2015, Treprostinil administration attenuates bleomycin‐induced lung fibrosis in mice. [abstract], Eur Resp J, 46, PA3837
Cited by
Nathan, S. D., Waxman, A., Rajagopal, S., Case, A., Johri, S., DuBrock, H., De La Zerda, D. J., Sahay, S., King, C., Melendres-Groves, L., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00165-x · Cited by 152
Li, X., Zhu, L., Wang, B., Yuan, M., & Zhu, R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00855 · Cited by 107
The vascular perspective on acute and chronic lung disease
Borek, I., Birnhuber, A., Voelkel, N. F., Marsh, L. M., & Kwapiszewska, G. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170502 · Cited by 103
Group 3 Pulmonary Hypertension: From Bench to Bedside
Singh, N., Dorfmüller, P., Shlobin, O. A., & Ventetuolo, C. E. (2022) · Circulation Research · doi:10.1161/circresaha.121.319970 · Cited by 98
Nathan, S. D., Behr, J., Cottin, V., Lancaster, L., Smith, P., Deng, C., Pearce, N., Bell, H., Peterson, L., & Flaherty, K. R. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001310 · Cited by 73
Metadata
- Authors
- Nikitopoulou, I., Manitsopoulos, N., Kotanidou, A., Tian, X., Petrovic, A., Magkou, C., Ninou, I., Aidinis, V., Schermuly, R. T., Kosanovic, D., & Orfanos, S. E.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- GP Livanos and M Simou Laboratories 1st Department of Critical Care & Pulmonary Services Medical School National & Kapodistrian University of Athens Evangelismos Hospital Athens Greece
- Universities of Giessen and Marburg Lung Center Member of the German Center for Lung Research (DZL) Justus‐Liebig University Giessen Germany
- Justus-Liebig-Universität Gießen (DE)
- Department of Pathology Evangelismos Hospital Athens Greece
- Alexander Fleming Biomedical Sciences Research Center (GR)
- Sechenov University (RU)
- Corresponding author
- Orfanos, Stylianos E.
- Venue
- Pulmonary Circulation
- Publisher
- Wiley
- Published
- 2019-10
- Volume
- 9
- Issue
- 4
- Pages
- 1-14
- ISSN
- 2045-8932 (ISSN-L)
- 2045-8940
- PMC
- PMC6883672
- OpenAlex
- W2976822390
- Cited by
- 44
- References
- 62
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 6 · 2020: 5 · 2019: 1
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor, 31 d)
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Pulmonary Circulation (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- United Therapeutics Corporation (TRE-NC-004)
- Galenica-Ferrer (1348/2015)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- treprostinil, prostacyclin analogues, pulmonary fibrosis, bleomycin-induced lung injury, vascular remodeling, pulmonary hypertension, NF-κB signaling, lung inflammation, collagen deposition, VE-cadherin, bronchoalveolar lavage fluid, lung mechanics, prophylaxis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Orotracheal treprostinil administration attenuates bleomycin‐induced lung injury, vascular remodeling, and fibrosis in mice. https://app.cochat.ai/papers/10.1177/2045894019881954
- The paper
- Nikitopoulou, I., Manitsopoulos, N., Kotanidou, A., Tian, X., Petrovic, A., Magkou, C., Ninou, I., Aidinis, V., Schermuly, R. T., Kosanovic, D., & Orfanos, S. E. (2019). Orotracheal treprostinil administration attenuates bleomycin‐induced lung injury, vascular remodeling, and fibrosis in mice. Pulmonary Circulation. https://doi.org/10.1177/2045894019881954
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.